TRAXENS
17.7.2019 08:32:11 CEST | Business Wire | Press release
Traxens, expert in providing high-value data and services for the supply chain industry, today announces that it has closed a Series C funding round worth close to €20M ($22.7M), led by the Itochu Corporation, Bpifrance and Supernova Invest (Crédit Agricole Innovations et Territoires Fund).
This financing will enable the company to launch a global large-scale sea-land fleet of IoT tracking solutions on vessels operated by its partner shipping companies, including CMA CGM and MSC. Traxens expects to have 100,000 containers (both dry and reefer containers) equipped with its solution by end of 2020, making it one of the major players in the IoT for smart containers industry. This number is set to grow even higher after Traxens announced in June 2019 that Maersk will become a shareholder and customer with an initial order for up to 50,000 containers.
Traxens’ Internet-of-Things solution is based on a patented, breakthrough technology that enables access to the most comprehensive, precise and timely data for managing assets in transit anywhere in the world. This technology brings improved efficiency and security, greater transparency and enhanced asset utilization, while opening up new opportunities for shipping companies.
“This Series C funding round is a major milestone that consolidates our strategy and will enable us to deploy our solution at a significant scale in the coming years,” said Jacques Delort, managing director of Traxens. “The financing will help us to reach critical mass quickly as a data producer in a booming market. We will increase the visibility of the company in existing and new markets as well as that of our solution, while our first commercial partnership shows the great potential of our solution.”
“Traxens offers an innovative solution for the supply chain industry. We believe that the collaboration with Traxens will enable us to develop epoch-making products and services in the field of Big Data/IoT, which fits in perfectly with ITOCHU group’s growth strategy,” said Shunsuke Noda, ITOCHU Corporation’s CDO・CIO. “In addition to our investment, we are looking forward to our role as Traxens partner to grow the sales of its products and services in Asia, a region where sea-land traffic is booming.”
“We are delighted to make this investment in Traxens, a company we know well,” said Emmanuel Audouard, director at Bpifrance. “Our objective is to support ground-breaking innovations and we are convinced Traxens is very well positioned to become a global leader in the promising field of smart container management.”
“We are delighted to invest in Traxens, it benefits from outstanding commercialized products and services, and from unique partnerships with the largest shipping companies. We believe Traxens has what it takes to become a global leader in the smart container industry,” said Julien Cristiani, partner at Supernova Invest.
According to IDC , worldwide technology spending on the Internet of Things is set to reach $1.2T (€1.06T) in 2022, attaining a CAGR of 13.6% over the 2017-2022 forecast period.
Traxens already counts major BCOs among its customers, such as the world’s largest chemical manufacturer, BASF, and partners with major shipping lines to provide bespoke tracking data for containers. It recently launched a pilot IoT project in the Spanish port of Valencia with the objective of improving operational efficiency by using Traxens’ solutions to monitor container movement in the port.
Advisors
Bpifrance: Emmanuel Audouard, Muriel Prudent, Valentin Dubois, Ha-Jin Shin de Bruchard
Itochu: Shunsuke Noda, Stephan Lubrano
Supernova Invest: Julien Cristiani
Legal Advisors - Traxens: Nova Partners – Loic Pellegrino
Legal advisors - Bpifrance and Supernova Invest: Degroux Brugère – Jérémie Swiecznik
Legal advisors - Itochu: Ashurst – Anne Reffay
Financial & fundraising advisors: MRFT & Co – Mathieu Rouget
About ITOCHU Corporation
ITOCHU is listed on the Tokyo Stock Exchange and was founded in 1858 when its founder, Chubei Itoh, commenced linen trading operations. Since then, ITOCHU has evolved and grown over 150 years and is now one of the leading Sogo Shosha (general trading company). ITOCHU has approximately 110 bases in 63 countries and engages in domestic trading, import/export, and overseas trading of various products such as textiles, machinery, metals, minerals, energy, chemicals, food, general products, realty, information and communications technology, and finance, as well as business investment.
About Bpifrance
Bpifrance is the French national investment bank. It finances businesses at every stage of their development through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
www.bpifrance.fr and presse.bpifrance.fr – Follow us on Twitter: @Bpifrance – @BpifrancePresse
About Supernova Invest
Supernova Invest is an independent venture capital firm that has strong relationships with the CEA, one of the world’s leading research organizations, and with Amundi, the largest asset manager in Europe. Investments focus on companies developing disruptive innovations operating in the life sciences, energy & environment, industrial, microelectronics and digital sectors. Today, Supernova Invest manages or advises five funds totaling €250 million ($284M) and has invested in more than 100 start ups since 1999. Supernova Invest is based in France.
https://supernovainvest.com/en/
About Traxens
Traxens generates, collects, consolidates, enriches and transforms logistics asset data into an easily understandable format enabling effective decision-making. The company’s breakthrough Internet-of-Big-Things technology provides comprehensive, real-time information for managing logistics assets anywhere in the world. Traxens’ solutions digitally transform multimodal supply chains, enabling customers to reduce costs, optimize investments, comply with environmental regulations and deliver premium services to their customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190716005938/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom